clinical trial · NCT01582269
A Study in Recurrent Glioblastoma (GB)
Eli Lilly and Company·phase2·completed·n = 158
GlioblastomaGalunisertibLomustinePlacebo
brief summary
The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer
started
Apr 26, 2012
primary completion
Jul 26, 2014
completion
Oct 10, 2024
last updated
Nov 24, 2025
official title
A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol